This company is no longer active
Pieris Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Pieris Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pieris Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 1 | -16 | -28 | -28 | N/A |
| 6/30/2024 | 21 | -24 | -38 | -38 | N/A |
| 3/31/2024 | 41 | -16 | -50 | -50 | N/A |
| 12/31/2023 | 43 | -25 | -54 | -54 | N/A |
| 9/30/2023 | 47 | -28 | -47 | -47 | N/A |
| 6/30/2023 | 33 | -27 | -46 | -46 | N/A |
| 3/31/2023 | 17 | -41 | -49 | -48 | N/A |
| 12/31/2022 | 26 | -33 | -61 | -60 | N/A |
| 9/30/2022 | 28 | -35 | -59 | -58 | N/A |
| 6/30/2022 | 27 | -42 | -65 | -64 | N/A |
| 3/31/2022 | 27 | -47 | -19 | -18 | N/A |
| 12/31/2021 | 31 | -46 | -9 | -8 | N/A |
| 9/30/2021 | 25 | -51 | -11 | -10 | N/A |
| 6/30/2021 | 24 | -48 | -3 | -3 | N/A |
| 3/31/2021 | 32 | -38 | -44 | -43 | N/A |
| 12/31/2020 | 29 | -37 | -49 | -46 | N/A |
| 9/30/2020 | 45 | -26 | -50 | -46 | N/A |
| 6/30/2020 | 57 | -15 | -56 | -52 | N/A |
| 3/31/2020 | 51 | -22 | -57 | -52 | N/A |
| 12/31/2019 | 46 | -28 | -55 | -52 | N/A |
| 9/30/2019 | 34 | -36 | -49 | -48 | N/A |
| 6/30/2019 | 27 | -40 | -51 | -49 | N/A |
| 3/31/2019 | 33 | -28 | -49 | -48 | N/A |
| 12/31/2018 | 29 | -27 | -3 | -1 | N/A |
| 9/30/2018 | 42 | -8 | 1 | 3 | N/A |
| 6/30/2018 | 38 | -8 | N/A | 53 | N/A |
| 3/31/2018 | 28 | -18 | N/A | 55 | N/A |
| 12/31/2017 | 25 | -18 | N/A | 50 | N/A |
| 9/30/2017 | 10 | -32 | N/A | 48 | N/A |
| 6/30/2017 | 7 | -31 | N/A | 9 | N/A |
| 3/31/2017 | 6 | -27 | N/A | 9 | N/A |
| 12/31/2016 | 6 | -23 | N/A | -14 | N/A |
| 9/30/2016 | 5 | -19 | N/A | -10 | N/A |
| 6/30/2016 | 5 | -17 | N/A | -10 | N/A |
| 3/31/2016 | 4 | -15 | N/A | -7 | N/A |
| 12/31/2015 | 3 | -14 | N/A | -13 | N/A |
| 9/30/2015 | 4 | -15 | N/A | -10 | N/A |
| 6/30/2015 | 4 | -13 | N/A | -8 | N/A |
| 3/31/2015 | 4 | -13 | N/A | -8 | N/A |
| 12/31/2014 | 5 | -10 | N/A | -5 | N/A |
| 9/30/2014 | 6 | -5 | N/A | -6 | N/A |
| 12/31/2013 | 12 | 0 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if PIRS's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if PIRS's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if PIRS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if PIRS's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if PIRS's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PIRS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/16 03:06 |
| End of Day Share Price | 2024/12/13 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pieris Pharmaceuticals, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Biren Amin | Jefferies LLC |